Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Hematology|September 10, 2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromesMadlen Jentzsch, Christine Döhring, Richard Linke, et al.
Cancers|November 27, 2021
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell TransplantationDonata Backhaus, Madlen Jentzsch, Lara Bischof, et al.
Frontiers in Oncology|December 27, 2021
Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary SyndromeGeorg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, et al.
Frontiers in Oncology|March 18, 2020
Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell SarcomaAnne Sophie Kubasch, Georg-Nikolaus Franke, Ali Aldaoud, et al.
American Journal of Hematology|July 21, 2021
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Transfusion|December 11, 2021
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39)Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, et al.
Journal of Cancer Research and Clinical Oncology|October 2, 2015
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantationChristian Pfrepper, Anne Klink, Gerhard Behre, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Annals of Hematology|October 15, 2025
Total thrombus formation analysis in patients with myeloid neoplasia and thrombocytopeniaKatharina Freitag, Georg-Nikolaus Franke, Maria Weise, et al.
Annals of Hematology|March 13, 2024
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practicesGeorg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, et al.
Pageof 8